These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32932518)

  • 1. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
    Strati P; Jain P; Johnson RJ; Forbes S; Feng L; Samaniego F; Rodriguez MA; Fayad LE; Hagemeister F; Westin J; Wang M; Neelapu SS; Nastoupil LJ; Fowler NH
    Blood; 2021 Feb; 137(8):1124-1129. PubMed ID: 32932518
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in follicular lymphoma.
    Flowers CR; Leonard JP; Fowler NH
    Blood; 2020 Jun; 135(24):2133-2136. PubMed ID: 32236519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Duodenal Follicular Lymphoma Treated With Rituximab Monotherapy and Followed-up for 15 Years.
    Seki A; Iwamuro M; Yoshioka M; Fujii N; Okada H; Nose S; Takata K; Yoshino T; Yamamoto K
    Acta Med Okayama; 2015; 69(5):301-6. PubMed ID: 26490027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
    Nastoupil LJ
    Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide plus rituximab (R
    Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
    Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma.
    Cheson BD; Morschhauser F; Martin P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):563-571. PubMed ID: 32303486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
    Junlén HR; Lockmer S; Kimby E; Wahlin BE
    Ann Hematol; 2020 Oct; 99(10):2357-2366. PubMed ID: 32808106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
    Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
    J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
    J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Refractory AITL treatment with rituximab plus lenalidomide: a case report].
    Wei C; Zhang L; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):809-811. PubMed ID: 34289578
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
    Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
    Leonard JP; Jung SH; Johnson J; Pitcher BN; Bartlett NL; Blum KA; Czuczman M; Giguere JK; Cheson BD
    J Clin Oncol; 2015 Nov; 33(31):3635-40. PubMed ID: 26304886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab maintenance in elderly patients with follicular lymphoma.
    Casulo C
    Leuk Res; 2019 Jan; 76():96-97. PubMed ID: 30578039
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab maintenance in follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):158-61. PubMed ID: 26352422
    [No Abstract]   [Full Text] [Related]  

  • 18. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
    Jacobson CA; Freedman AS
    Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: A Review in Previously Treated Follicular Lymphoma.
    Blair HA
    Drugs; 2020 Sep; 80(13):1337-1344. PubMed ID: 32803669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Agents in Follicular Lymphoma.
    Ysebaert L; Morschhauser F
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.